BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 26164026)

  • 1. Nesiritide Therapy Is Associated With Better Clinical Outcomes Than Dobutamine Therapy in Heart Failure.
    Kong LG; Wang CL; Zhao D; Wang B
    Am J Ther; 2017; 24(2):e181-e188. PubMed ID: 26164026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dobutamine Therapy is Associated with Worse Clinical Outcomes Compared with Nesiritide Therapy for Acute Decompensated Heart Failure: A Systematic Review and Meta-Analysis.
    Wang XC; Zhu DM; Shan YX
    Am J Cardiovasc Drugs; 2015 Dec; 15(6):429-37. PubMed ID: 26123415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
    Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
    Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure.
    Gerhard T; Zineh I; Winterstein AG; Hartzema AG
    Pharmacotherapy; 2006 Jan; 26(1):34-43. PubMed ID: 16509026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of nesiritide (human b-type natriuretic peptide) and dobutamine on heart rate variability in decompensated heart failure.
    Aronson D; Burger AJ
    Am Heart J; 2004 Nov; 148(5):e16. PubMed ID: 15523294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study.
    Burger AJ; Horton DP; LeJemtel T; Ghali JK; Torre G; Dennish G; Koren M; Dinerman J; Silver M; Cheng ML; Elkayam U;
    Am Heart J; 2002 Dec; 144(6):1102-8. PubMed ID: 12486437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.
    Silver MA; Horton DP; Ghali JK; Elkayam U
    J Am Coll Cardiol; 2002 Mar; 39(5):798-803. PubMed ID: 11869844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF).
    Gheorghiade M; Gattis WA; Adams KF; Jaffe AS; O'Connor CM; ;
    Am Heart J; 2003 Feb; 145(2 Suppl):S55-7. PubMed ID: 12594453
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC.
    Mehra MR; McCluskey T; Barr M; Bourge RC; Jessup ML; Mancini D; Radovancevic B; Rayburn B; Taylor DO; Lilly-Hersley J; Linde P
    Am Heart J; 2007 Jun; 153(6):932-40. PubMed ID: 17540193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of nesiritide in patients with acute decompensated heart failure.
    O'Connor CM; Starling RC; Hernandez AF; Armstrong PW; Dickstein K; Hasselblad V; Heizer GM; Komajda M; Massie BM; McMurray JJ; Nieminen MS; Reist CJ; Rouleau JL; Swedberg K; Adams KF; Anker SD; Atar D; Battler A; Botero R; Bohidar NR; Butler J; Clausell N; Corbalán R; Costanzo MR; Dahlstrom U; Deckelbaum LI; Diaz R; Dunlap ME; Ezekowitz JA; Feldman D; Felker GM; Fonarow GC; Gennevois D; Gottlieb SS; Hill JA; Hollander JE; Howlett JG; Hudson MP; Kociol RD; Krum H; Laucevicius A; Levy WC; Méndez GF; Metra M; Mittal S; Oh BH; Pereira NL; Ponikowski P; Tang WH; Tanomsup S; Teerlink JR; Triposkiadis F; Troughton RW; Voors AA; Whellan DJ; Zannad F; Califf RM
    N Engl J Med; 2011 Jul; 365(1):32-43. PubMed ID: 21732835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes associated with nesiritide administration for acute decompensated heart failure in the emergency department observation unit: a single center experience.
    Styron JF; Jois-Bilowich P; Tallman T; Emerman C; Starling RC; Frank Peacock W
    Congest Heart Fail; 2009; 15(3):103-7. PubMed ID: 19522957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials.
    Sackner-Bernstein JD; Kowalski M; Fox M; Aaronson K
    JAMA; 2005 Apr; 293(15):1900-5. PubMed ID: 15840865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of death with nesiritide.
    Burger AJ
    JAMA; 2005 Aug; 294(8):897; author reply 898. PubMed ID: 16118377
    [No Abstract]   [Full Text] [Related]  

  • 14. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
    Abraham WT; Adams KF; Fonarow GC; Costanzo MR; Berkowitz RL; LeJemtel TH; Cheng ML; Wynne J; ;
    J Am Coll Cardiol; 2005 Jul; 46(1):57-64. PubMed ID: 15992636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure.
    de Lissovoy G; Stier DM; Ciesla G; Munger M; Burger AJ
    Am J Cardiol; 2003 Sep; 92(5):631-3. PubMed ID: 12943895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of patients hospitalized for acute decompensated heart failure: does nesiritide make a difference?
    Carroll RJ; Mulla ZD; Hauck LD; Westbrook A
    BMC Cardiovasc Disord; 2007 Nov; 7():37. PubMed ID: 18039381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of standard heart failure therapy and concomitant treatment with intravenous furosemide or inotropes (dobutamine, dopamine, and/or milrinone) on renal function and mortality in patients treated with nesiritide.
    Kurien S; Warfield KT; Wood CM; Miller WL
    Am J Cardiol; 2006 Dec; 98(12):1627-30. PubMed ID: 17145223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure.
    Tang WH; Wu Y; Grodin JL; Hsu AP; Hernandez AF; Butler J; Metra M; Voors AA; Felker GM; Troughton RW; Mills RM; McMurray JJ; Armstrong PW; O'Connor CM; Starling RC
    JACC Heart Fail; 2016 Jan; 4(1):68-77. PubMed ID: 26656144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF).
    van Deursen VM; Hernandez AF; Stebbins A; Hasselblad V; Ezekowitz JA; Califf RM; Gottlieb SS; O'Connor CM; Starling RC; Tang WH; McMurray JJ; Dickstein K; Voors AA
    Circulation; 2014 Sep; 130(12):958-65. PubMed ID: 25074507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).
    Greene SJ; Hernandez AF; Sun JL; Metra M; Butler J; Ambrosy AP; Ezekowitz JA; Starling RC; Teerlink JR; Schulte PJ; Voors AA; Armstrong PW; O'Connor CM; Mentz RJ
    Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.